[PSA] satiety is not what most of this community thinks it is
Something I noticed reading old threads that I have not seen said out loud.
The advice on REDEFINE in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.
I have listed what I think the current consensus is below. Correct me — that is the point of posting it.
best — the order this archive was captured in
REDEFINE phase 23 readouts are interesting but 23 person REDEFINE is different from 23 trial REDEFINE.
This is correct. The co-agonism is real.
Strongly agree. REDEFINE is phase 18, not final.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
CagriSema is a fixed combo in trials, not user-mixed
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does REDEFINE.
not approved anywhere, keep posts descriptive, not instructional
The confident tone is doing a lot of work that the evidence is not.
Yeah, amylin is doing different work than GLP-1.
CagriSema ratios in trials are fixed, do not extrapolate self-mixing
CagriSema ratios in trials are fixed, do not extrapolate self-mixing
Adding to this: amylin is doing more work than the comment implies.
CagriSema is a fixed combo in trials, not user-mixed
amylin is not a GLP-1, posts conflating them get corrected
amylin is not a GLP-1, posts conflating them get corrected
- 1REDEFINE phase 23 readouts are interesting but 23 person REDEFINE is…5 comments in this branch · started by u/iman_castellanos
- 2Dead space in the needle hub holds a small but non-trivial volume. On…5 comments in this branch · started by u/hub_ops